Drug
Gr2301
Gr2301: highest development phase Phase 2, developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| GR2301 injection NCT07930039 | Phase 2 | Vitiligo |
Latest
No recent events.
Follow Gr2301 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.